Health and Healthcare
Short Sellers Run for Cover From Major Biotechs
Published:
Last Updated:
The short interest data are out for the most recent settlement date, June 28. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.
As we have said before, FDA rulings can make or break the biotech stocks, and short sellers and mega-bulls often go to war against each other in these companies. After all, if a single failed clinical trial can mean disaster for a stock, then some short sellers can argue for a stock implosion down the road.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The June 28 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Amgen Inc. (NASDAQ: AMGN) saw its short interest decrease to 8.70 million shares from the previous level of 9.45 million. Shares were last seen trading at $182.27, in a 52-week range of $166.30 to $210.19.
Short interest in Biogen Inc. (NASDAQ: BIIB) decreased to 2.87 million shares from the previous 3.96 million. The stock recently traded at $232.43, within a 52-week range of $216.12 to $388.67.
Celgene Corp.’s (NASDAQ: CELG) short interest for this settlement date decreased to 9.68 million shares from the previous level of 10.87 million. Shares were changing hands at $93.59, in a 52-week range of $58.59 to $98.97.
Gilead Sciences Inc. (NASDAQ: GILD) saw its short interest drop to 11.90 million shares from 12.58 billion in the previous period. Shares were trading at $67.46, in a 52-week range of $60.32 to $79.61.
The number of MannKind Corp. (NASDAQ: MNKD) shares short grew to 39.79 million. The previous reading was 35.24 million. The stock was trading at $1.14 a share, in a 52-week range of $0.94 to $3.04.
Alexion Pharmaceuticals Inc.’s (NASDAQ: ALXN) short interest declined to 3.19 million shares from the previous 3.30 million. Shares were trading at $124.20, in a 52-week range of $92.56 to $141.86.
24/7 Wall St.Credit Card Companies Are Doing Something Nuts
Credit card companies are at war. The biggest issuers are handing out free rewards and benefits to win the best customers.
It’s possible to find cards paying unlimited 1.5%, 2%, and even more today. That’s free money for qualified borrowers, and the type of thing that would be crazy to pass up. Those rewards can add up to thousands of dollars every year in free money, and include other benefits as well.
We’ve assembled some of the best credit cards for users today. Don’t miss these offers because they won’t be this good forever.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
